Cancer drug resistance: A fleet to conquer

Journal of Cellular Biochemistry - Tập 120 Số 9 - Trang 14213-14225 - 2019
Showket Hussain1, Ankita Singh1, Sheeraz Un Nazir1, Sonam Tulsyan2, Asiya Khan3, Ramesh Kumar4, Nasreena Bashir5, Pranay Tanwar3, Ravi Mehrotra2
1Division of Cellular and Molecular Diagnostics, National Institute of Cancer Prevention and Research, Noida, India
2Division of Preventive Oncology, National Institute of Cancer Prevention and Research, Noida, India
3Department of Lab Oncology, AIIMS, New Delhi, India
4Department of Biochemistry, Bundelkhand University, Jhansi, India
5College of Applied Medicine, King Khalid University, Abha, Saudi Arabia

Tóm tắt

Abstract

Cancer is a disease that claims millions of lives each year across the world. Despite advancement in technologies and therapeutics for treating the disease, these modes are often found to turn ineffective during the course of treatment. The resistance against drugs in cancer patients stems from multiple factors, which constitute genetic heterogeneity like gene mutations, tumor microenvironment, exosomes, miRNAs, high rate of drug efflux from cells, and so on. This review attempts to collate all such known and reported factors that influence cancer drug resistance and may help researchers with information that might be useful in developing better therapeutics in near future to enable better management of several cancers across the world.

Từ khóa


Tài liệu tham khảo

10.1002/path.1706

10.1158/0008-5472.CAN-12-2217

10.1038/sj.onc.1206951

10.1038/nrc706

10.1146/annurev.biochem.71.102301.093055

10.1038/nrc1074

10.1159/000474453

10.1016/j.leukres.2012.04.008

10.1038/nature07399

10.1038/jhg.2012.87

10.1126/science.8122112

10.1186/1475-2867-5-30

10.1146/annurev.pharmtox.39.1.361

10.3109/03602532.2014.901348

10.1016/j.lungcan.2006.06.019

10.1038/sj.pcan.4500394

10.1038/bjc.1997.414

10.1002/cncr.21227

10.1158/0008-5472.CAN-06-3307

10.1097/SLA.0b013e3181cc939f

10.1093/jnci/djq102

10.1158/0008-5472.CAN-08-0180

10.1016/0005-2736(81)90512-5

10.1016/j.addr.2012.06.011

10.1242/jcs.113.19.3365

10.1016/j.jprot.2010.06.006

10.1016/j.gde.2013.02.017

10.1038/ncb2574

10.1182/blood-2009-08-239228

10.1016/j.cyto.2010.09.002

10.1002/jcp.1041400308

10.1371/journal.pone.0047480

10.1021/pr200434y

10.1093/nar/gkr828

10.1002/pmic.200900351

10.1016/j.ctrv.2011.06.005

10.1126/science.1090599

10.1371/journal.pone.0047786

10.1161/ATVBAHA.112.300139

10.1016/j.molcel.2010.06.014

10.1002/cncr.27895

10.1095/biolreprod.111.093252

10.3389/fonc.2013.00019

10.1586/epr.09.17

10.1097/00001622-200011000-00008

10.1038/aps.2013.35

10.1038/nrc3498

10.1002/pmic.201200398

10.1016/j.ceb.2014.05.004

10.1016/j.bbcan.2014.10.001

10.1158/1535-7163.MCT-05-0102

10.1371/journal.pone.0050999

10.1080/15384101.2015.1005530

10.1007/s10549-014-3037-0

10.1007/s13277-014-2242-0

10.1016/j.ygyno.2014.12.042

10.1093/jnci/djv135

10.1126/scisignal.2003084

10.1038/onc.2008.49

10.1016/j.ccr.2012.02.022

10.1038/nrc1094

10.1016/j.yexcr.2010.02.045

10.1038/nm.3394

10.1152/physrev.1996.76.1.69

10.1126/science.1090922

10.1016/j.cell.2013.03.020

10.1038/nrc1877

10.1084/jem.20140692

10.1016/j.semcdb.2009.10.001

10.1038/nrc1477

10.4161/cc.5.15.3112

Pietras K, 2002, Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy, Cancer Res, 62, 5476

10.1016/1040-8428(93)90004-N

Pietras K, 2001, Inhibition of platelet‐derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors, Cancer Res, 61, 2929

10.1158/1078-0432.CCR-09-1001

10.1158/0008-5472.CAN-07-5714

10.1158/1541-7786.MCR-12-0030

10.3389/fonc.2018.00173

10.3390/ijms13089545

10.7150/jca.10865

10.1074/jbc.C300173200

10.1172/JCI26532

10.1074/jbc.M110.168617

10.1089/ten.tea.2013.0473

10.1038/nature11183

10.1038/nm.1908

10.1038/nrd3870

10.1200/JCO.2015.62.8719

10.1126/science.1171362

10.1016/j.ccr.2014.04.005

10.1016/j.ccr.2014.04.021

10.1038/nrc2714

10.1136/gutjnl-2012-302529

10.1016/j.ccr.2012.01.007

10.1101/cshperspect.a006486

10.1158/0008-5472.CAN-12-4354

10.1126/science.1235122

10.1128/MCB.24.14.6172-6183.2004

10.3322/caac.20138

10.1126/scisignal.2004149

10.18632/oncotarget.802

10.1126/science.1062538

10.1038/nrc3237

10.1038/nrd2871

10.1158/2159-8290.CD-12-0400

10.1016/j.tibs.2011.03.006

10.1126/scitranslmed.3002003

10.1016/j.ccr.2009.11.022

10.1101/gad.186965.112

10.1158/2159-8290.CD-12-0018

10.1016/j.ccr.2010.10.031

10.1038/onc.2010.626

10.1158/2159-8290.CD-11-0085

10.1016/j.ccr.2012.10.023

10.1172/JCI0215468

10.1080/19336918.2015.1016686

10.3389/fphar.2015.00279

10.3390/cancers10020036

10.4110/in.2017.17.4.214

10.21037/atm.2016.12.09

10.1038/nature11249

10.2174/09298673113209990226